- ►annals.org [PDF] K Anderson, JS Jacobson, DF Heitjan, JG … - Annals of internal medicine, 2006 - Am Coll Physicians Background: For BRCA1 or BRCA2 mutation carriers, decision analysis indicates
that prophylactic surgery or chemoprevention leads to better survival than
surveillance alone. ... Objective: To evaluate the cost-effectiveness of ... Cited by 42 - Related articles - BL Direct - All 5 versions
WS Rubinstein - Journal of Clinical Oncology, 2005 - jco.ascopubs.org Carriers of BRCA1 and BRCA2 mutations face a cruel choice. Their best chance for
long-term survival comes at the price of removing their female organs. It is a
bitter antidote to the probabilistic predictions about their ill-fated ... Cited by 9 - Related articles - All 8 versions
VR Grann, JS Jacobson, V Sundararajan, SM … - The cancer journal from Scientific American - ncbi.nlm.nih.gov PURPOSE: This study was conducted to obtain and compare the preferences assigned
to cancer states and prevention measures by women who had breast cancer, were at
high risk for breast cancer, or had neither condition. PATIENTS AND ... Cited by 31 - Related articles - BL Direct
- ►ascopubs.org JB Madalinska, J Hollenstein, E Bleiker, M … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org RESULTS: No statistically significant between-group differences were observed in
generic QOL (Short Form-36), with women in both the PBSO and GS groups scoring
similarly to the general population. Compared with GS, PBSO was associated ... Cited by 50 - Related articles - All 12 versions
- ►ascopubs.org VR Grann, JS Jacobson, D Thomason, D … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org MATERIALS AND METHODS: Markov modeling of outcomes was performed in a simulated
cohort of 30-year-old women who tested positive for BRCA1/2 mutations. The model
incorporated breast and ovarian cancer incidence rates from the literature ... Cited by 96 - Related articles - BL Direct - All 8 versions
- ►ascopubs.org MS van Roosmalen, LCG Verhoef, PFM … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org METHODS: A Markov model was developed to compare LE and QALE following four
strategies: (1) prophylactic mastectomy and prophylactic oophorectomy (PMPO),
(2) screening for breast cancer and prophylactic oophorectomy (BSPO), (3) ... Cited by 69 - Related articles - BL Direct - All 10 versions
- ►jcojournal.org K Armstrong, JS Schwartz, T Randall, SC … - Journal of Clinical Oncology, 2004 - jcojournal.org From the Department of Medicine, Center for Clinical Epidemiology and
Biostatistics, and Department of Obstetrics and Gynecology, University of
Pennsylvania School of Medicine; Leonard Davis Institute of Health ... Cited by 73 - Related articles - BL Direct - All 7 versions
- ►thelancet.com SM Domchek, TM Friebel, SL Neuhausen, T … - Lancet Oncology, 2006 - Elsevier In the primary analysis, mean follow-up from BPSO to censoring was 3·1 years
[SD 2·4] in the BPSO group and 2·1 years [2·0] in the non-BPSO group. The
hazard ratio (HR) for overall mortality was 0·24 (95% CI 0·08–0·71), ... Cited by 80 - Related articles - All 14 versions
TM Friebel, SM Domchek, SL Neuhausen, T … - Clinical Breast Cancer, 2007 - CIG Media Group Background: Women with BRCA1 or BRCA2 (BRCA1/2) mutations can reduce cancer
incidence and mortality by using bilateral prophylactic oophorectomy (BPO) or
bilateral prophylactic mastectomy (BPM). The avail- ability of these risk- ... Cited by 4 - Related articles - BL Direct - All 3 versions
- ►oxfordjournals.org HM Klaren, LJ van't Veer, FE van Leeuwen, … - JNCI Journal of the National Cancer Institute, 2003 - jnci.oxfordjournals.org Women who carry a germline mutation in the BRCA1 or BRCA2 (BRCA1/2) gene have a
50%–80% lifetime risk of developing breast cancer and a 10%–40% lifetime
risk of developing ovarian cancer (1–4). These high-risk women are being ... Cited by 54 - Related articles - BL Direct - All 7 versions
